Pronac

Quick links to important sections

Pronac

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pronac

Quick Facts

Property Description
Active Ingredients Acetyl Cysteine, Diclofenac
Form Ophthalmic Solution (Eye Drops)
Pharmacological Class NSAID and Mucolytic Agent Combination
General Purpose Managing Ocular Inflammation and Protecting the Cornea
Origin Synthetic Compound

What Type of Medicine Is Pronac and Its Primary Components?

Pronac is a synthetic, fixed-dose combination ophthalmic solution, classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and mucolytic agent combination. This medication is specially formulated for topical ocular administration, applied directly to the surface of the eye. The two key active ingredients are Diclofenac and Acetyl Cysteine. Diclofenac is recognized for its anti-inflammatory effects, which work by inhibiting the body’s inflammatory pathways. Pronac is differentiated by its combination approach, targeting both inflammatory processes and tissue integrity, which is distinct from single-agent ocular NSAID products.

Composition and Form: The Dual-Action Ocular Delivery System

The active ingredients are presented in a sterile, aqueous ophthalmic solution (eye drops) suitable for topical application. The inclusion of Diclofenac primarily serves to address localized pain and swelling. Complementing this, Acetyl Cysteine functions as an antioxidant and a mucolytic agent. This mucolytic action is involved in modifying secretions and maintaining corneal clarity. The topical solution ensures the anti-inflammatory and protective elements reach the affected external tissues locally, concentrating the therapeutic effect.

General Purpose: Why Are These Two Agents Combined in Pronac?

The primary purpose of combining these two synthetic agents is the integrated management of discomfort and the support of corneal tissue integrity. This dual mechanism allows Pronac to address symptomatic inflammation—by reducing pain and swelling—while also mitigating potential complications from secretions and oxidative stress. A typical application involves the supportive management of the eye following certain surgical procedures or in conditions involving significant surface inflammation. This combined approach provides comprehensive support for the outer layers of the eye, offering a targeted solution where both strong anti-inflammatory action and tissue protection are required.

What side effects are possible with Pronac?

Possible Side Effects and Safety Information

The officially documented safety profile for Pronac, an ophthalmic solution containing a Non-Steroidal Anti-Inflammatory Drug (NSAID) and a mucolytic agent, centers on the risk of local ocular adverse reactions.

Transient burning and stinging upon application, along with lacrimation complaints (increased tearing), are among the most frequently reported ocular effects. Other common ocular adverse reactions listed in regulatory documents include blurred vision, eye pain, irritation, itching, and injection (redness). Systemic reactions reported in a small percentage of patients (leq 3%) include headache, dizziness, and nausea.

Serious safety concerns documented in postmarketing experience relate to corneal integrity. These include the risk of corneal epithelial breakdown, thinning, erosion, ulceration, and perforation, which are considered potentially sight-threatening events. Topical NSAIDs may also slow or delay healing.

Safety constraints and population-specific considerations are explicitly noted. Use is officially recommended to be avoided during late pregnancy due to the risk of effects on the fetal cardiovascular system. Furthermore, individuals with specific ocular comorbidities like corneal epithelial defects, diabetes mellitus, or rheumatoid arthritis may face an increased risk of severe corneal events. The labeling specifies that prolonged use postsurgery (beyond 14 days) may increase the severity of corneal adverse reactions. The medicine must not be used while wearing soft contact lenses.

Overdose and Emergency Response

The official regulatory documents define the overdose profile for Pronac (Diclofenac/Acetyl Cysteine Ophthalmic Solution) based on the route of exposure. Topical overdosage of the ophthalmic solution is documented to not ordinarily cause acute problems when applied as intended. However, the primary concern is accidental systemic ingestion, which may lead to significant toxicity from the Diclofenac (NSAID) component.

In the event of accidental ingestion or suspected systemic overdose, immediate medical attention is required, and individuals must seek medical help right away by contacting emergency services or a poison control center. Symptoms documented in regulatory sources for systemic NSAID overdose include nausea, vomiting, diarrhea, stomach pain, dizziness, drowsiness, blurred vision, and tinnitus (ringing in the ears).

More severe outcomes officially noted include gastrointestinal bleeding, seizures, coma, high or low blood pressure, and renal compromise (little or no urine output). Treatment is strictly symptomatic and supportive, and official guidance states that no specific antidote is known. If the solution is accidentally ingested, fluids should be taken to dilute the medication.

Both children and adults are susceptible to severe systemic harm, and elderly patients are at increased risk for serious gastrointestinal events. Monitoring procedures often require checking vital signs and performing ECG, blood, and urine tests.

Therapeutic Uses of Pronac

Main Uses and Therapeutic Indications

Pronac is a non-steroidal anti-inflammatory drug (NSAID) primarily used to manage pain and reduce inflammation. It belongs to the acetic acid derivative group and is indicated for the treatment of several acute and chronic conditions.

Relief of Pain and Inflammation

The primary function of Pronac is to inhibit the production of prostaglandins, which are chemicals in the body that signal pain and promote inflammation. By reducing these substances, the medication helps manage symptoms associated with:

  • Osteoarthritis: Relief of joint pain, stiffness, and swelling caused by the wear and tear of cartilage.
  • Rheumatoid Arthritis: Management of chronic inflammation in the joints and surrounding tissues.
  • Ankylosing Spondylitis: Reduction of pain and stiffness in the spine and sacroiliac joints.
  • Acute Musculoskeletal Disorders: Treatment of localized pain resulting from sprains, strains, or other soft tissue injuries.

Management of Menstrual Pain

Pronac is frequently utilized for the treatment of primary dysmenorrhea. It helps alleviate the cramping and systemic discomfort associated with menstrual cycles by lowering uterine prostaglandin levels.

Postoperative and Acute Pain

In clinical settings, Pronac may be used to address short-term acute pain, such as discomfort following minor surgical procedures or dental work. Its anti-inflammatory properties are particularly effective in cases where tissue trauma has led to localized swelling and sensitivity.

Therapeutic Benefits

The use of Pronac provides several key benefits for patients managing inflammatory conditions:

  • Improved Mobility: By reducing joint swelling and stiffness, the medication can help individuals maintain or regain physical function and mobility.
  • Sustained Relief: Certain formulations are designed to provide consistent symptom control over several hours, which is particularly beneficial for chronic inflammatory diseases.
  • Targeted Action: The medication focuses specifically on the enzymatic pathways responsible for inflammation, providing localized relief at the site of injury or disease.

Regulatory References

  1. NIH DailyMed official label for Diclofenac Ophthalmic

Eligibility and Restrictions for Use

Who Can and Cannot Use Pronac?

The population eligibility for Pronac (Acetyl Cysteine, Diclofenac Ophthalmic Solution) is strictly defined by regulatory documentation. Use is established for adults (18 years and older) for labeled indications, provided no contraindications are present.


Absolute Contraindications

The medicine is contraindicated and must not be used by specific populations:

  • Hypersensitivity: Individuals with known allergy to Diclofenac, Acetyl Cysteine, or any component of the formulation.
  • NSAID Cross-Reactivity: Patients in whom asthma, urticaria, or acute rhinitis is precipitated by Aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
  • Late Pregnancy: Women starting at 30 weeks of gestation (late pregnancy) due to risks associated with the Diclofenac component.

Eligibility Restrictions

Population Group Eligibility Status (Regulatory Basis)
Pediatric Population (<18 years) Use Not Established (Safety and effectiveness have not been verified).
Pregnancy (pre-30 weeks) Restricted Use (Permitted only if potential benefit justifies potential risk).
Lactation (Breastfeeding) Conditional Use (Decision required to discontinue nursing or discontinue the drug).
High-Risk Comorbidities Conditional Use (Requires caution in patients with corneal defects, diabetes, rheumatoid arthritis, or bleeding tendencies).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation defines the interaction profile of Pronac (Diclofenac + Acetyl Cysteine Ophthalmic Solution) based on local, pharmacodynamic effects at the ocular surface, as systemic absorption of the active ingredients from eye drops is negligible.

Documented Pharmacodynamic Interactions

Interaction Entity Official Interaction Outcome (Regulatory Language)
Topical Corticosteroids (Ophthalmic) Co-administration may increase the potential for healing problems and slow or delay corneal healing.
Medications that prolong bleeding time May cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Caution is advised for patients with known bleeding tendencies.
Other Non-Steroidal Anti-Inflammatory Drugs Potential for cross-sensitivity is noted with acetylsalicylic acid and other NSAIDs.

Administration Timing Requirements

When co-administering Pronac with other topical ophthalmic medications, regulatory practice mandates a separation of at least 5 minutes between instillations. This timing rule is necessary to prevent the washout of the preceding medication and ensure proper drug concentration on the ocular surface. No systemic metabolic or transporter-mediated drug interactions are documented in the prescribing information due to the topical route and limited systemic exposure.

Mechanism of Action

How Pronac Works: Mechanism of Action

The action of Pronac is defined by two complementary pharmacodynamic domains that target both the initiation and the consequences of inflammatory signaling on the ocular surface.


Modulating the Inflammatory Signal Cascade

This mechanism centers on Diclofenac, which acts as an inhibitor of the Cyclooxygenase (COX) enzymes. By blocking the activity of COX-1 and COX-2, the drug suppresses the local biosynthesis of prostaglandins and other key eicosanoids . This action intervenes early in the inflammatory signal cascade, resulting in the modulation of physiological responses that involve local vasodilation and nociceptor sensitization.


Dual Action: Mucus Rheology and Oxidative Stress

This secondary domain involves Acetyl Cysteine, which exerts a dual chemical and biochemical function. It uses its free sulfhydryl groups to cleave the disulfide bonds within high-viscosity mucin glycoproteins, leading to the depolymerization of mucin oligomers. Simultaneously, Acetyl Cysteine enhances the cellular antioxidant capacity by acting as a precursor to Glutathione (GSH), which influences the local regulation of oxidative processes on corneal tissues. The combination targets both enzymatic pathways and chemical structures within the ocular surface.

Dosage and Administration Information

How to Use Pronac

Pronac is formulated exclusively as an ophthalmic solution (eye drops) for topical ocular administration, meaning it is only applied directly to the surface of the eye. Clinical guidelines define the specific, short-term administration protocol, which is structured based on the reason for its use. The medicine is not intended for injection, oral ingestion, or long-term chronic management.

Standardized Usage Protocol

The approved regimen for adults requires the application of one drop to the affected eye(s) at a frequency of four times daily (QID). The duration of this course is strictly limited to the acute post-operative phase. For inflammation following cataract surgery, use continues for up to 14 days (two weeks). Following refractive surgery, the course duration is limited to up to 3 days.

Administration Aspect Guideline
Route Topical Ocular Application
Dosing One drop per affected eye, four times daily (QID)
Timing Treatment should begin 24 hours after surgery
Duration (Max) 14 days (Post-Cataract) or 3 days (Post-Refractive)

Procedural Conditions and Population Rules

Specific instructions govern the proper application of the solution. When other topical ophthalmic products are necessary, an interval of at least 5 to 10 minutes is required between the application of Pronac and the other product. Soft contact lenses must be removed prior to application, with re-insertion deferred for approximately 15 minutes. Regarding specific populations, safety and effectiveness in pediatric patients (under 18) have not been established, while older adults typically require no general dose adjustment.

The use of this medicine is defined entirely by this standardized, time-bound protocol, which confines its administration exclusively to the acute recovery period as specified by established clinical protocols.

Recent Clinical Evidence

Research Evidence Overview for Pronac

Evidence for Postoperative Ocular Inflammation and Pain Management

Studies conducted during periods of increased symptom activity after eye surgery have primarily used Randomized Controlled Trials (RCTs). The research explored short-term symptom changes and monitored objective measures of inflammation, such as swelling in the anterior chamber, along with patient-reported outcomes describing perceived discomfort. These studies were generally carried out on adults following routine cataract or refractive surgery.

Research highlights changes measured during the study period, with data showing patterns related to a change in measured inflammation and pain scores in the observed populations. These findings are largely described in the context of the anti-inflammatory component (Diclofenac).

Evidence for Preventing Cystoid Macular Oedema (CME)

Research explored its use in the context of a complication called Cystoid Macular Oedema (CME), which may occur after cataract surgery. Studies monitored changes in macular thickness using advanced imaging technology like Optical Coherence Tomography (OCT). Data show patterns related to incidence measured during the study period for the NSAID component in the observed populations when compared to certain other treatment strategies.

The specific role of the Acetyl Cysteine component was not the central element of the large, high-level trials used to study CME prevention. Data are still emerging, and there is limited information for long-term outcomes concerning the sustained preventive effect beyond the typical intermediate-term follow-up of one to three months.

Evidence for Supporting Corneal Surface Issues and Problematic Secretions

Research explored short-term symptom changes in conditions associated with acute episodes, such as corneal abrasions. The research also evaluated the mucolytic component (Acetyl Cysteine) for conditions marked by functional limitations related to problematic ocular secretions. Findings indicate that the application of the mucolytic component was associated with patterns related to ocular comfort in certain conditions. Follow-up durations were limited across many key trials, meaning that long-term effects are not fully established.

Key Studies & References

  1. Diclofenac Ophthalmic Solution: Official Labeling and Indications for Postoperative Inflammation and Pain
  2. NICE Guideline: Cataracts in adults: management (Supporting evidence for postoperative care)

Frequently Asked Questions (FAQ)

Common questions about Pronac (FAQ)


Q: How quickly does Pronac typically start working?

A: Studies reviewing the diclofenac component of Pronac suggest a reduction in pain may be observed within approximately two hours after the application of the eye drops. This information helps establish general expectations for when the anti-inflammatory effect begins.


Q: How long do the effects of Pronac usually last?

A: Pharmacological studies, including non-human research, indicate that the anti-inflammatory effect has a half-life of approximately 10 hours. This duration of effect is cited as the basis for the four-times daily frequency noted in the prescribing information.


Q: Does Pronac require a special monitoring while using it?

A: Official patient information emphasizes that regular eye examinations by an eye care professional are typically advised during the course of treatment. The purpose of this monitoring is to ensure the medicine is achieving its intended effect and to check for any unwanted effects, particularly concerning corneal health.


Q: Can I drive or operate machinery while using Pronac?

A: Official safety information reports that common side effects can include temporary blurred vision and dizziness. Patients who experience these effects are advised to exercise caution regarding activities that require clear vision, such as driving or operating machinery.


Q: Do experts recommend taking Pronac in the morning or evening?

A: Regulatory instructions define the standard regimen as application four times daily (QID). This frequency is established to maintain consistent medication coverage throughout the specified course of treatment. Official information does not specify which clock times (like morning or evening) are recommended, focusing instead on the frequency of application.


Q: Can I take ibuprofen or acetaminophen while using Pronac?

A: The regulatory warnings advise caution due to a potential for cross-sensitivity with acetylsalicylic acid and other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes ibuprofen. Regarding acetaminophen, the negligible systemic absorption of Pronac from the eye drops means a specific systemic drug-drug interaction is not documented in the official labeling.


Q: Does Pronac interact with common over-the-counter vitamins or supplements?

A: According to the official product information, systemic absorption of the active ingredients from the eye drops is considered negligible. As a result of this topical route, no systemic drug interactions, including those with common over-the-counter vitamins or supplements, are documented in the prescribing information.


Q: Can men and women use Pronac the same way?

A: The official administration protocol and dosing instructions for Pronac are standardized for all adult patients (18 years and older). Regulatory information does not contain any gender-specific requirements or differences regarding how the medicine should be used.


Q: What happens if I miss a dose of Pronac?

A: Patient guidelines based on regulatory information generally recommend applying the missed dose as soon as it is remembered. However, if it is almost time for the next application, the missed dose should be skipped entirely. Official guidelines state that doses should not be doubled to compensate for a missed application.


Q: Are there any foods or drinks I should avoid while taking Pronac?

A: Because Pronac is administered directly to the eye and has negligible systemic absorption, there are no specific warnings documented in the official labeling concerning interactions with food or common drinks.


Q: Can Pronac affect my sleep pattern?

A: Safety documents for the diclofenac component of the ophthalmic formulation have included sleep problems, such as insomnia, in the list of reported side effects. This is noted as a potential effect that may be experienced during treatment.


Q: Will Pronac show up on a standard drug test?

A: The active ingredient, diclofenac, is classified as a non-steroidal anti-inflammatory drug (NSAID). It is not designated as a controlled substance and is not typically included in the substances screened for on standard drug tests.


Q: Does Pronac have a withdrawal effect if I stop taking it?

A: Regulatory documentation does not identify the active ingredients in Pronac as agents associated with potential dependence or abuse. Therefore, significant withdrawal effects upon the cessation of use are not listed in the official prescribing information.


Q: Are there different strengths of Pronac?

A: The official labeling defines the product as an ophthalmic solution with a standard concentration of the active ingredients. No alternative strengths or concentrations are cited in the official prescribing information.


Q: Does Pronac cause weight gain?

A: Official safety profiles for systemic NSAIDs, which include diclofenac, have noted associations with edema (fluid retention) and unusual weight gain. While this effect is not specifically reported in clinical trials for the ophthalmic solution, the systemic adverse reaction profile notes this potential.


Q: Can Pronac affect birth control pills?

A: Due to the medicine’s topical application and negligible systemic absorption into the body, no systemic drug interactions, including those involving oral birth control pills, are documented in the official prescribing information.


Q: Is Pronac addictive?

A: Regulatory documentation pertaining to drug abuse and dependence does not list the active ingredients in Pronac as agents associated with a potential for abuse or addiction.


Q: What does 'contraindication' mean for Pronac?

A: A contraindication is a key medical term detailed in the official label of a drug. It identifies a specific situation, condition, or patient population where the drug is not to be used, as the risk of harm clearly outweighs any potential therapeutic benefit.


Q: Can Pronac affect my kidney function?

A: The clinical pharmacology section indicates that systemic exposure following topical ocular administration is very limited. Therefore, the systemic levels of the diclofenac component are typically not expected to cause clinically significant changes in kidney (renal) function.


Q: Are there specific symptoms that mean Pronac is working?

A: The medication is observed to be achieving its intended effect when there is a reduction in the symptoms of ocular inflammation. This includes experiencing decreased pain, swelling, and redness in the affected eye, which are the main outcomes measured in clinical studies.


Q: Does drinking alcohol while using Pronac cause severe side effects?

A: Due to the medicine’s topical route and negligible systemic absorption into the bloodstream, there are no specific warnings or documentation in the official labeling regarding an interaction between Pronac and the consumption of alcohol.


Q: What does 'Black Box Warning' mean for Pronac?

A: A Black Box Warning is the strongest warning required by the FDA to inform the public of potentially serious or life-threatening risks. While this warning exists for oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), it does not typically apply to ophthalmic solutions like Pronac because of the negligible amount of the medicine absorbed systemically.


Q: What is the purpose of the non-active ingredients in Pronac?

A: The non-active ingredients, or excipients, are included in the formulation for technical reasons. Their purpose is to ensure the medicine is delivered as a stable, sterile, and buffered liquid solution that is safe and tolerable for topical application to the eye's surface.

How should Pronac be stored and disposed of?

How to Store and Dispose of Pronac

The storage and disposal of Pronac (diclofenac sodium ophthalmic solution) must strictly follow official regulatory guidelines to maintain potency and safety.

Storage Requirements

Item Requirement
Temperature Store at Controlled Room Temperature (15 C to 30 C) [2.2, 2.9].
Protection Must be protected from light and kept from freezing [2.1, 2.4].
Container Keep the container tightly closed and store in its original container [2.1, 2.5].
Child Safety Keep out of the sight and reach of children [2.6, 2.7].

Disposal Instructions

Official disposal protocols prioritize safety and environmental protection. The preferred method for discarding unused or expired Pronac is through a drug take-back program or mail-back envelope [1.3, 1.8]. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (e.g., dirt, kitty litter) and placed in a sealed bag before being thrown in the household trash [1.4]. The medicine is not on the official list of products recommended for flushing [1.1].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pronac found in:

A-Z Index: